NOTES TO THE COMPANY FINANCIAL STATEMENTS 41.
ADOPTION OF NEW AND REVISED STANDARDS The impact on the Company of new and revised standards is the same as for the Group.
Details are given in Note 1 to the consolidated nancialstatements.
SIGNIFICANT ACCOUNTING POLICIES The separate financial statements of the Company are presented as required by the Companies Act 2006.
As permitted by that Act, the separate financial statements have been prepared in accordance with International Financial Reporting Standards and UK company law.
The financial statements have been prepared on the historical cost basis.
The principal accounting policies adopted are the same as those set out in Note 2 to the consolidated financial statements with the addition of the policies noted below.
Investments in subsidiaries are stated at cost less, where appropriate, provisions for impairment.
Equity-settled employee share schemes are accounted for in accordance with IFRIC 11 Group and Treasury Share Transactions, whereby current charge expenses relating to the subsidiaries employees are recharged to subsidiary companies.
INVESTMENTS IN SUBSIDIARIES Investments in subsidiaries represent the following: Ownership % Ownership % Ordinary Shares Ordinary Shares Companys name Established in 2012 2011 Hikma Limited UK 100 100 Hikma Pharma Limited Jersey 100 100 Hikma Holdings UK Limited UK 100 Hikma Acquisitions UK Limited UK 100 Al Jazeera Pharmaceutical Industries Ltd JPI KSA 52.5 52.5 Hikma Pharmaceuticals Limited Jordan 22.8 22.8 Hikma MENA Holdings UAE 100 100 AMKI MENA Holdings UAE 100 Hi n. V. N kma I ternational N etherlands 100 The investments in subsidiaries are all stated at cost.
The remaining shares are held by other Group companies.
The movement in the carrying value of the investments in the year represents an increase in the investment in Hikma MENA Holdings of$13,400,000 and a new investment in AMKI MENA Holdings of $2,722.
During the year ended 31 December 2012, Hikma undertook an internal reorganisation of the Group subsidiary structure.
The ultimate interest in all subsidiaries remains unchanged.
The changes in ownership immediately below the Company were the addition of Hikma International N. V. and Hikma Acquisitions UK Limited and the removal of Hikma Holdings UK Limited.
DUE FROM SUBSIDIARIES 2012 2011 Non-current assets $000 $000 Hikma Investment Ltd. 8,512 8,384 West-Ward Pharmaceuticals Corp. 50,628 37,952 Hikma Italia S. p. A 3,959 3,782 Hikma Pharma Limited Jersey 6,980 7,206 70,079 57,324 These balances represent loans that carry interest of 1.5% to 4.8% 2011: 1.5% to 4.8% per annum charged on the outstanding loan balances.
160 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012
